ClinicalTrials.gov
ClinicalTrials.gov Menu

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 (EBOVAC-Salone)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02509494
Recruitment Status : Recruiting
First Posted : July 28, 2015
Last Update Posted : February 28, 2018
Sponsor:
Collaborators:
London School of Hygiene and Tropical Medicine
Ministry of Health and Sanitation of Sierra Leone
College of Medicine and Allied Health Sciences (COMAHS)
University of Oxford
Institut National de la Santé Et de la Recherche Médicale, France
Grameen Foundation
World Vision of Ireland
Information provided by (Responsible Party):
Janssen Vaccines & Prevention B.V.

June 24, 2015
July 28, 2015
February 28, 2018
September 30, 2015
May 3, 2019   (Final data collection date for primary outcome measure)
  • Number of Participants With Adverse Events [ Time Frame: Up to 28 days after the third vaccination in stage 1; Up to 28 days after each vaccination in stage 2 ]
  • Number of participants With Serious Adverse Events [ Time Frame: Up to Day 360 post third vaccination; up to 2 years post-prime in stage 2 ]
  • Number of Participants with Solicited local and systemic adverse events [ Time Frame: Up to 7 days after each vaccination ]
  • Serum concentration of antibodies binding to EBOV GP [ Time Frame: Up to Day 360 post third vaccination; up to 2 years post-prime in stage 2 ]
    Blood samples will be collected from all subjects from Stage 1 and 2 to assess humoral immune responses to the vaccines over time
  • Number of participants With Serious Adverse Events [ Time Frame: Continuous throughout the duration of the study (up to Day 360 ± 1 month) ]
  • Number of Participants With Adverse Events [ Time Frame: Up to 56 days post-boost vaccination ]
  • Number of Participants with Solicited local and systemic adverse events [ Time Frame: Up to 7 days ]
  • Serum concentration of neutralizing antibodies to Ebola virus glycoprotein (EBOV GP) and antibodies binding to EBOV GP [ Time Frame: At day of prime and boost vaccinations, and at day 240 (± 1 month) and Day 360 (± 1 months) ]
    Blood samples will be collected from all subjects from Stage 1 and 2 to assess humoral immune responses to the vaccines over time
Complete list of historical versions of study NCT02509494 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2
A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola
The purpose of this study is the evaluation of the safety and immunogenicity of two candidate Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo, in a heterologous prime-boost regimen.
This is staged Phase 3 study to gather information on the safety and immunogenicity of a heterologous prime-boost regimen. In this regimen, Ad26.ZEBOV will be administered as a prime vaccination, then boosted with the candidate vaccine MVA-BN-Filo and later the third vaccination using Ad26.ZEBOV will be administered 2 years post prime vaccination to participants in Stage 1 who consent to this. The study will take place in Sierra Leone and will consist of a screening phase, an active phase (vaccination) and a follow-up phase. The active phase of the study will be conducted initially in two stages. In the first stage approximately 40 adults aged 18 years or older will be vaccinated to gain information about the safety and immunogenicity of the prime-boost regimen. In stage 2 a larger group of approximately 976 individuals will be vaccinated to further evaluate the safety and immunogenicity of the prime-boost-post prime regimen across different age groups. In this stage, children aged 1 year or older, adolescents and adults will be included. Solicited local and systemic adverse events will be collected until 7 days after the prime and boost vaccination. Unsolicited adverse events will be collected from signing of the informed consent form (ICF) onwards until 56 days after the boost vaccination in Stage 1 and then again from the day of the third vaccination until 28 days after the third vaccination, and until 28 days after the prime vaccination in Stage 2, and then again until 28 days after the boost vaccination. Serious adverse events will be collected from signing of the ICF onwards until 12 and 36 months after the prime vaccination in Stage 2 and Stage 1, respectively. These data will be reviewed by an independent data monitoring committee (IDMC) to assess whether initiation of vaccination in the next stage or age group can be provided. Safety evaluations will include assessment of adverse events, which will be monitored throughout the study. Participants in Stage 2 will be followed up for safety and immunogenicity until 12 months (children and adolescents) or 24 months (adults) after the prime vaccination. Participants in Stage 1 will be followed up for safety and immunogenicity until 36 months after the prime vaccination or until 1 year after the third vaccination.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Healthy
  • Biological: Ad26.ZEBOV
    Ebola Zaire vaccine, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles.
  • Biological: MVA-BN-Filo
    MVA‐BN‐Filo‐ is a live replication incompetent vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit (Inf. U.).
  • Biological: Menveo
    Menveo WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
  • Biological: Placebo
    0.9% saline for injection
  • Experimental: Stage 1: Active vaccination
    Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (prime); MVA-BN-Filo will be administered as a 0.5 mL IM injection (boost). The third vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post prime).
    Interventions:
    • Biological: Ad26.ZEBOV
    • Biological: MVA-BN-Filo
  • Experimental: Stage 2: Active vaccination
    Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (prime); MVA-BN-Filo will be administered as a 0.5 mL IM injection (boost). Children aged less than 2 years at randomization will receive a third vaccination at 3 months post boost with Placebo.
    Interventions:
    • Biological: Ad26.ZEBOV
    • Biological: MVA-BN-Filo
  • Active Comparator: Stage 2: Control vaccination
    Menveo will be administered as a 0.5 mL IM injection on Day 1 (prime) and placebo on Day 57 (boost).
    Interventions:
    • Biological: Menveo
    • Biological: Placebo
  • Active Comparator: Stage 2: Control vaccination for children
    Menveo will be administered as a 0.5 mL IM injection on Day 1 (prime) and placebo on Day 57 (boost). Children aged less than 2 years at randomization will receive a third vaccination at 3 months post boost with Menveo.
    Interventions:
    • Biological: Menveo
    • Biological: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1019
440
May 13, 2019
May 3, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria Stage 1 and 2:

  • Documented community engagement from community leader and a signed inform consent form (ICF) from each participant must be available
  • Participant Stage 1 must be 18 years or older at screening and be resident in selected study community with no intention to move from study area within the next 5 months
  • Participant must be healthy with no abnormalities in laboratory screening tests within 28 days before prime vaccination
  • Female participants of childbearing potential must use adequate birth control measures and must have a negative pregnancy test at screening and immediately prior to each study vaccination
  • Participant must pass the test of understanding (TOU)

Additional Inclusion criteria Stage 2:

  • One year or older at screening (children of enrolled parents are eligible)
  • Parent/legal guardian (for children) must pass the TOU before signing the ICF
  • Subjects aged 7 years and older will be asked to give positive assent in the presence of a witness

Exclusion Criteria:

  • Diagnosed with EVD or under quarantine/exposed to Ebola or body temperature equal of >= 38 degree Celsius (fever)
  • Having an acute illness (mild in nature that can be treated at home) or any clinically significant acute/chronic medical condition or having a decreased number of red blood cells/hemoglobin in the blood (anemia)
  • Previously participated in another Ebola interventional study or received any Ad26/MVA-based candidate vaccine
  • Vaccinated with live attenuated vaccines within 30 days or with inactivated vaccines 15 days before prime vaccination
  • Treated with an immunosuppressive drug at the time of screening

Additional exclusion criteria:

- Children up to 5 years of age with severe malnutrition (underweight or Z-score weight <2)

Sexes Eligible for Study: All
1 Year and older   (Child, Adult, Senior)
Yes
Contact: Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions: JNJ.CT@sylogent.com
Sierra Leone
 
 
NCT02509494
CR107372
VAC52150EBL3001 ( Other Identifier: Janssen Vaccines & Prevention B.V. )
115854 EBOVAC1 ( Other Grant/Funding Number: The Trial is financed within the IMI-2 Ebola program )
Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Janssen Vaccines & Prevention B.V.
Janssen Vaccines & Prevention B.V.
  • London School of Hygiene and Tropical Medicine
  • Ministry of Health and Sanitation of Sierra Leone
  • College of Medicine and Allied Health Sciences (COMAHS)
  • University of Oxford
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Grameen Foundation
  • World Vision of Ireland
Study Director: Janssen Vaccines & Prevention B.V. Clinical Trial Janssen Vaccines & Prevention B.V.
Janssen Vaccines & Prevention B.V.
February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP